- Home
- IAG vs ICLR Comparison
IAG vs ICLR Comparison
Compare IAG & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IAG | ICLR |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 9.3B |
| IPO Year | 2002 | 2001 |
Fundamental Metrics
Financial Performance| Metric | IAG | ICLR |
|---|---|---|
| Price | $16.44 | $172.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $17.75 | ★ $178.62 |
| AVG Volume (30 Days) | ★ 5.5M | 1.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $44.70 | N/A |
| Revenue Next Year | $1.11 | N/A |
| P/E Ratio | $18.66 | ★ $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.69 | $66.57 |
| 52 Week High | $24.87 | $211.00 |
Technical Indicators
Market Signals| Indicator | IAG | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 72.86 |
| Support Level | $15.52 | $156.94 |
| Resistance Level | $18.31 | $193.87 |
| Average True Range (ATR) | 0.80 | 7.84 |
| MACD | 0.00 | 1.90 |
| Stochastic Oscillator | 41.80 | 79.63 |
Price Performance
Historical ComparisonAbout IAG Iamgold Corporation
Iamgold Corp is a mid-tier gold mining company. The company operating gold mines are divided into geographic segments such as Cote Gold mine - Canada, Burkina Faso - Essakane mine, Westwood mine - Canada. The company's s non-gold mine segments are Exploration and evaluation and development, and Corporate - which includes royalty interests. The company generates the majority of its revenue from the Cote Gold mine segment.
About ICLR ICON plc
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.